8-K: Alkermes' ALKS 7290 Shows Promise in ADHD Phase 1 Study

Alkermes plc announced positive topline results from a Phase 1 proof-of-concept study for ALKS 7290, an investigational orexin 2 receptor agonist for ADHD, demonstrating clinically meaningful symptom improvements.

Summary

• Alkermes plc has announced positive topline results from a Phase 1 proof-of-concept study for ALKS 7290, an investigational orexin 2 receptor (OX2R) agonist.
• The study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ALKS 7290 in healthy volunteers and adults with ADHD.
• ALKS 7290 was generally well tolerated at all doses tested in both groups.
• In adults with ADHD, ALKS 7290 demonstrated dose-dependent, clinically meaningful improvements in ADHD symptoms as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS) and Clinical Global Impression-Severity Scale (CGI-S) at day 14.
• Median reductions in AISRS total scores were 14.0 points for the 20 mg dose and 19.0 points for the 50 mg dose.
• Median reductions in CGI-S scores were 1.0 for the 20 mg dose and 2.0 for the 50 mg dose, shifting disease severity from markedly/moderately ill to mildly ill.
• The study also included EEG-based biomarkers and cognitive tests showing treatment effects in domains like processing speed, information processing, working memory, and attention.
• A Phase 2 study is currently enrolling to further evaluate the safety and efficacy of ALKS 7290 in adults with ADHD, with data expected in 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, indicating promising early-stage results for a novel ADHD treatment candidate.

Positives

• Demonstrated clinically meaningful improvements in ADHD symptoms (AISRS and CGI-S) in adults with ADHD.
• ALKS 7290 was generally well tolerated across all doses tested in both healthy volunteers and adults with ADHD.
• No serious treatment-emergent adverse events (TEAEs) were reported.
• The drug showed dose-dependent effects supporting the selected dose range for Phase 2.
• Exploratory endpoints indicated positive effects on cognitive domains relevant to ADHD.
• The first-in-patient study provides early clinical evidence for orexin receptor agonism in ADHD treatment.
• No discontinuations due to adverse events were reported for participants receiving ALKS 7290.

Negatives

• The study was not designed or powered to detect statistically significant differences between treatment groups.
• The most common TEAEs included insomnia, pollakiuria, dizziness, change in sustained attention, micturition urgency, and constipation.
• Two participants in the placebo group discontinued the study.

Risks

• Clinical study results for ALKS 7290 may not be predictive of results of future stages of ongoing clinical studies, future clinical studies or real-world results.
• Clinical studies for ALKS 7290 may not be initiated or completed on expected timelines or at all.
• ALKS 7290 may be shown to be ineffective or unsafe in future studies.
• The FDA may not agree with the company's regulatory strategies or components of its development program for ALKS 7290.
• Potential changes in the cost, scope, and duration of the ALKS 7290 development program.

Future Outlook

A Phase 2 study evaluating the safety and efficacy of ALKS 7290 in adults with ADHD is currently enrolling, with data expected in 2027. The company is exploring the potential of orexin biology beyond hypersomnolence disorders.

Management Comments

• "These data provide early evidence supporting the potential of the orexin pathway to influence the brains neural networks that are linked to ADHD and suggest that ALKS 7290 could represent a meaningful new therapeutic approach for patients."
• "This exploratory, first-in-patient study was designed to provide early insights into the potential of orexin 2 receptor agonism as a novel treatment for adults with ADHD, and we are excited to see the emerging clinical profile of ALKS 7290."
• "The results begin to build the foundation of our understanding of ALKS 7290, and we look forward to further evaluating its safety and efficacy in our ongoing well-powered phase 2 study."

Industry Context

StockSavvy.ai notes that the development of novel therapies for ADHD is a significant area of focus in the neuroscience sector. The orexin pathway, previously primarily associated with sleep disorders, is now being explored for other neurological conditions, presenting a potential new therapeutic avenue.

Stakeholder Impact

• Shareholders may see increased interest in Alkermes due to promising early-stage results for a new drug candidate.
• Patients with ADHD may benefit from the potential development of a new therapeutic option.
• Healthcare providers will be interested in the ongoing development and potential future efficacy and safety data of ALKS 7290.

Next Steps

• Continue enrollment in the ongoing Phase 2 study of ALKS 7290 in adults with ADHD.
• Evaluate safety and efficacy data from the Phase 2 study, expected in 2027.
• Further explore the potential of orexin biology for other neurological disorders.

Key Dates

Recommendation

The filing presents positive early-stage (Phase 1) data for a novel ADHD candidate, ALKS 7290. While promising, these results are preliminary and not statistically powered. The company is moving to Phase 2, with data expected in 2027. Given the early stage and the inherent risks in drug development, a 'hold' recommendation is appropriate, pending further data from the Phase 2 study.

Keywords

ADHD, ALKS 7290, Orexin 2 Receptor Agonist, Phase 1 Study, Clinical Trial, Neuroscience, Attention Deficit Hyperactivity Disorder, Pharmacokinetics